In this study, we aimed to investigate the prognostic significance of HER2-low status in HR+/HER2 negative (HER2-) metastatic BC (MBC) patients treated with endocrine therapy (ET) plus palbociclib as first line. The gene discussed is ERBB2; the disease is breast cancer.